Physician profile
Jose D Rivera
NPI 1225144868
$5,883.10
in general payments reported to CMS, 2019-2025
10 companies · $96.39 in 2025
The $96.39 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,543 · 2020: $171 · 2021: $357 · 2022: $198 · 2023: $288 · 2024: $230 · 2025: $96.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,487.03 | 2019-2023 | Xarelto |
| Pfizer INC. | $1,750.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $557.87 | 2019-2024 | Lifevest |
| Medtronic, INC. | $528.51 | 2019-2025 | Micra, Na |
| Astrazeneca Pharmaceuticals LP | $187.86 | 2019-2025 | Lokelma, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $106.47 | 2022-2024 | Eliquis |
| Pbg Puerto Rico LLC | $86.55 | 2019-2023 | |
| Boston Scientific Corporation | $81.29 | 2021 | |
| Amgen INC. | $79.78 | 2020-2025 | Repatha |
| Abbott Laboratories | $17.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.